Effect of the R92H and A379V Genotypes of Platelet-activating Factor Acetylhydrolase on Its Enzyme Activity, Oxidative Stress and Metabolic Profile in Chinese Women with Polycystic Ovary Syndrome

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2017 Mar 22

PMID 28320416

Citations 5

Authors

Renjiao Zhang

Qi Song

Hongwei Liu

Huai Bai

Yujin Zhang

Qingqing Liu

Linbo Guan

Ping Fan

Affiliations

Soon will be listed here.

Abstract

Background: The G994T polymorphism in platelet-activating factor acetylhydrolase (PAF-AH) gene is associated with the risk of polycystic ovary syndrome (PCOS). The aim of this study was to investigate the relationship between R92H and A379V variants of the PAF-AH gene and the risk of PCOS and to evaluate the effects of the genotypes on PAF-AH activities and clinical, metabolic and oxidative stress indexes in Chinese women.

Methods: A total of 862 patients with PCOS based on the Rotterdam consensus criteria and 750 control women from a population of Chinese Han nationality in the Chengdu area were studied from 2006-2015. PAF-AH genotypes were determined by PCR and restriction fragment length polymorphism analysis. Plasma PAF-AH, high-density lipoprotein (HDL)-associated PAF-AH (H-PAF-AH) and apolipoprotein (apo) B-containing lipoprotein-associated PAF-AH (apoB-PAF-AH) activities were measured using the trichloroacetic acid precipitation procedure with PAF C-16 as a substrate. Circulating markers of oxidative stress, including serum total oxidant status, total antioxidant capacity, oxidative stress index and malondialdehyde levels, and clinical and metabolic parameters were also analyzed.

Results: No significant differences were observed in the frequencies of R92H and A379V genotypes and alleles of the PAF-AH gene between PCOS and control groups (P > 0.05). Compared with patients with the 92RR genotype, patients with H allele of R92H (RH + HH genotype) had significantly higher plasma PAF-AH and apoB-PAF-AH activities (P < 0.05) and tended to exhibit increased H-PAF-AH activity (P = 0.063) after adjusted for age and BMI. However, when serum LDL-C, HDL-C, TG and HOMA index were added as covariates, the comparisons no longer remained statistical significance (P > 0.05). There were no significant differences in clinical, hormonal, metabolic and circulating oxidative stress parameters and the frequencies of PAF-AH G449T genotype according to PAF-AH R92H or A379V genotyping in patients with PCOS and control women.

Conclusions: There were no significant associations between R92H and A379V variants of PAF-AH gene and risk of PCOS in Chinese women. The increased plasma PAF-AH and apoB-PAF-AH activities in patients with H allele of R92H are related to the R92 → H variation, changes in plasma lipoprotein levels, insulin resistance, aging, and gaining weight and thus may be involved in the pathogenesis of PCOS and the increased risks of future cardiovascular diseases.

Citing Articles

Lipoprotein-associated phospholipase A2: The story continues.

Huang F, Wang K, Shen J Med Res Rev. 2019; 40(1):79-134.

PMID: 31140638 PMC: 6973114. DOI: 10.1002/med.21597.

Association of SOD2 A16V and PON2 S311C polymorphisms with polycystic ovary syndrome in Chinese women.

Liu Q, Liu H, Bai H, Huang W, Zhang R, Tan J J Endocrinol Invest. 2019; 42(8):909-921.

PMID: 30607774 DOI: 10.1007/s40618-018-0999-5.

Cardiometabolic risk in polycystic ovary syndrome.

Studen K, Pfeifer M Endocr Connect. 2018; 7(7):R238-R251.

PMID: 29844207 PMC: 6026886. DOI: 10.1530/EC-18-0129.

Effects of apoC1 genotypes on the hormonal levels, metabolic profile and PAF-AH activity in Chinese women with polycystic ovary syndrome.

Zhang R, Liu Q, Liu H, Bai H, Zhang Y, Guan L Lipids Health Dis. 2018; 17(1):77.

PMID: 29636060 PMC: 5894162. DOI: 10.1186/s12944-018-0725-5.

Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.

Santoso A, Maulana R, Alzahra F, Maghfirah I, Putrinarita A, Heriansyah T Am J Cardiovasc Dis. 2018; 7(6):122-133.

PMID: 29348973 PMC: 5768870.

References

Robert Y, Dubrulle F, Gaillandre L, Ardaens Y, Lemaitre L, Dewailly D . Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders: visual analysis versus computerized quantification. Fertil Steril. 1995; 64(2):307-12. View

Fan P, Liu H, Wang X, Zhang F, Song Q, Li Q . Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome. Hum Reprod. 2010; 25(5):1288-94. DOI: 10.1093/humrep/deq047. View

Li R, Zhang Q, Yang D, Li S, Lu S, Wu X . Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013; 28(9):2562-9. DOI: 10.1093/humrep/det262. View

Sanchez-Quesada J, Vinagre I, de Juan-Franco E, Sanchez-Hernandez J, Bonet-Marques R, Blanco-Vaca F . Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes. Cardiovasc Diabetol. 2013; 12:112. PMC: 3750253. DOI: 10.1186/1475-2840-12-112. View

Liu H, Zhang F, Fan P, Bai H, Zhang J, Wang Y . Effects of apolipoprotein E genotypes on metabolic profile and oxidative stress in southwest Chinese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013; 170(1):146-51. DOI: 10.1016/j.ejogrb.2013.04.016. View

Ciccone M, Favale S, Bhuva A, Scicchitano P, Caragnano V, Lavopa C . Anteroposterior diameter of the infrarenal abdominal aorta is higher in women with polycystic ovary syndrome. Vasc Health Risk Manag. 2009; 5(3):561-6. PMC: 2704897. DOI: 10.2147/vhrm.s5639. View

Fan P, Liu H, Wan D, Li Y, Song Q, Bai H . Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome. Fertil Steril. 2009; 92(6):2054-7. DOI: 10.1016/j.fertnstert.2009.06.022. View

. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2011; 27(1):14-24. DOI: 10.1093/humrep/der396. View

Fan P, Liu X, He G, Zhang S, Zhang J, Bai H . Maternal and fetal plasma platelet-activating factor acetylhydrolase activity and distribution in pre-eclampsia. Pediatr Res. 2012; 72(4):426-31. DOI: 10.1038/pr.2012.87. View

10.

Kruse S, Mao X, Heinzmann A, Blattmann S, Roberts M, Braun S . The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet. 2000; 66(5):1522-30. PMC: 1378003. DOI: 10.1086/302901. View

11.

Goodarzi M . Looking for polycystic ovary syndrome genes: rational and best strategy. Semin Reprod Med. 2008; 26(1):5-13. DOI: 10.1055/s-2007-992919. View

12.

Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale H . Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013; 19(3):268-88. DOI: 10.1093/humupd/dms059. View

13.

Zheng G, Xiong S, Chen H, Mei L, Wang T . Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population. Mol Biol Rep. 2014; 41(11):7141-51. DOI: 10.1007/s11033-014-3597-4. View

14.

Repaci A, Gambineri A, Pasquali R . The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2010; 335(1):30-41. DOI: 10.1016/j.mce.2010.08.002. View

15.

Lim S, Davies M, Norman R, Moran L . Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18(6):618-37. DOI: 10.1093/humupd/dms030. View

16.

Zhang R, Liu H, Bai H, Zhang Y, Liu Q, Guan L . Oxidative stress status in Chinese women with different clinical phenotypes of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2016; 86(1):88-96. DOI: 10.1111/cen.13171. View

17.

Hoffmann M, Winkler K, Renner W, Winkelmann B, Seelhorst U, Wellnitz B . Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). J Thromb Haemost. 2008; 7(1):41-8. DOI: 10.1111/j.1538-7836.2008.03216.x. View

18.

Liu P, Li Y, Wu H, Chao T, Tsai L, Lin L . Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction. J Thromb Haemost. 2006; 4(5):1023-8. DOI: 10.1111/j.1538-7836.2006.01895.x. View

19.

Casas J, Ninio E, Panayiotou A, Palmen J, Cooper J, Ricketts S . PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation. 2010; 121(21):2284-93. PMC: 3377948. DOI: 10.1161/CIRCULATIONAHA.109.923383. View

20.

Chen C . Platelet-activating factor acetylhydrolase: is it good or bad for you?. Curr Opin Lipidol. 2004; 15(3):337-41. DOI: 10.1097/00041433-200406000-00015. View